From molecular discovery to therapeutic innovation, we combine bioengineering with computational science to develop personalized treatments. Our research integrates genetic analysis, advanced biomarker detection, and quantitative modeling to accelerate the development of precise, effective therapies. See all of our research areas.
Advancing drug discovery and treatment optimization through computational modeling and systems-level analysis of biological processes.
Understanding how genetic variation impacts drug response to enable more precise and personalized therapeutic strategies.
Understanding how genetic variation impacts drug response to enable more precise and personalized therapeutic strategies.
Understanding how genetic variation impacts drug response to enable more precise and personalized therapeutic strategies.
$30M
14,000
Pioneering the analysis of over 14,000 biosynthetic gene clusters across 2,500 human-associated bacteria to discover new therapeutic compounds.
46th year
In 2025, and for the 46th consecutive year, the UCSF School of Pharmacy received more research funding from the National Institutes of Health (NIH) than any other pharmacy school.
Education
Tony Capra, PhD, first came to UCSF as a postdoctoral fellow, where he learned to apply computational methods to genetics and human evolution. Now a professor in the UCSF School of Pharmacy's Department of Bioengineering and Therapeutic Sciences, Capra develops computational and AI methods to better understand genetic variation, rare disease, and the biology that makes us human.
UC San Francisco and UC Berkeley have launched a joint program to develop the frontier of AI and biomedicine to accelerate advances in clinical care. James Fraser, PhD, a professor in the UCSF School of Pharmacy’s Department of Bioengineering and Therapeutic Sciences, is among the program's leaders.
Researchers at the UCSF Quantitative Biosciences Institute, Icahn School of Medicine at Mount Sinai, Institut Pasteur, and Fred Hutchinson Cancer Center, report that a single amino-acid change alters how a coronavirus protein interacts with the human and bat immune systems, shifting the body's response to infection.